IMDXEarnings•globenewswire•
IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
Sentiment:Negative (30)
Summary
NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its second quarter results:
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire